AIM ImmunoTech is trading 34.29% up now at $0.35 after announcing on August 31, 2026, that the USPTO granted a patent covering Ampligen combined with pembrolizumab across multiple cancer indications.
- The patent expires December 20, 2039, expanding oncology IP protection and potentially supporting the drug’s long-term commercial value.
- The announcement is the clearest company-specific catalyst; broader markets are modestly lower, making general sentiment unlikely. The August 27 investor conference and pancreatic-cancer trial milestones weren’t new on August 31.